Financial results of fiscal 2023 Net sales decrease organically by 1.6% to € 21.0 billion EBITDA pre down organically by 9.0% to € ...
The Change Healthcare Ransomware Payment Change Healthcare, a key player in the medical services sector owned by UnitedHealth Group, fell victim t...
AstraZeneca intends to invest £450 million to research, develop and manufacture vaccines in Speke, Liverpool, a facility which will be operationall...
ICIG acquires production facilities at five locations in Germany and U.S. Purchase price in low triple-digit million euro range Closing expected for mi...
GMP material to be used in Phase Ib study in platinum-resistant ovarian cancer (PROC) patients scheduled to start this year. Previously reported Phase I sa...
New site in Cajamar, São Paulo has 2.5 times more storage capacity than previous space in Cotia, São Paulo 13,000 square-meters space for ...
Alamar Biosciences, a company powering precision proteomics to enable the earliest detection of disease, is pleased to announce a strategic supply agreemen...
Clinical Microbiomics A/S^1, the global microbiome science company, announces the acquisition of DNASense ApS, an innovative Danish microbiome C...
NeuroBo Pharmaceuticals, Inc. (Nasdaq: NRBO), a clinical-stage biotechnology company focused on transforming cardiometabolic diseases, announced that...
BeiGene, Ltd. announced a new matching adjusted indirect comparison (MAIC) of the efficacy of BRUKINSA® (zanubrutinib) versus acalabrutinib in relapsed...
-Eurofins Discovery, an industry-leading provider of products and services for drug discovery research, announced the launch of DiscoveryAI SAFIRE (Suite o...
Expands Viatris' Portfolio of Innovative Assets by Immediately Adding Two Phase 3 Assets, Selato...
Global license and collaboration agreement set to advance the development of OSE-230, a monoclonal antibody aimed at resolving chronic inflammation. ...
Bristol Myers Squibb (NYSE: BMY) announced that it has successfully completed its acquisition of RayzeBio, Inc. (NASDAQ: RYZB). With the completion of the ...
© 2025 Biopharma Boardroom. All Rights Reserved.
